Arash Aslanabadi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Arash Aslanabadi has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Mahsa Hojabri
Institute of Human Virology University of Maryland School of Medicine Baltimore Maryland USA
3 shared publications Maryam Karimi
Institute of Human Virology University of Maryland School of Medicine Baltimore Maryland USA
3 shared publications- Mohammad Mohseni Sajadi
Institute of Human Virology, University of Maryland School of Medicine, Baltimore, USA
3 shared publications Abdolrahim Abbasi
Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA
2 shared publicationsAlonso Heredia
Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA
2 shared publicationsAnthony DeVico
Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA
2 shared publications
Latest Publications
- Open Access
- 1 September 2026
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 40 (19) , e70343
Preliminary Development and Assessment of a Multiplex Assay for Human Papillomavirus Antibody Detection Using Commercial L1 Proteins
Background: Human papillomavirus (HPV)‐associated cancers are preventable with vaccination. Serologic assays monitor antibody responses, but their complexity and cost pose limitations when evaluating population level immunity. We developed an L1‐based assay for the detection of multiple type‐specific HPV antibodies. Methods: The Luminex‐based assay used recombinant L1 proteins from seven HPVs (HPV‐6/11/16/18/35/45/58) for the detection of type‐specific immunoglobulin (Ig)G and IgA. Cutoffs were established using plasma from infants and children. The assay was optimized and qualified using a sample set from a blinded proficiency panel developed at the Frederick National Laboratory for Cancer Research. Results: Sensitivity and specificity for anti‐HPV‐6/11/16/18/58 IgG were 100% at the Mean + 3 standard deviation [SD] and Mean + 5 SD thresholds. Sensitivity for HPV‐45 was 100% and 92.9% at the +3 SD and +5 SD thresholds, respectively. IgA detection showed moderate positivity among vaccinated individuals, with peak estimates of 96.4% (HPV‐11) and 85.7% (HPV‐58) at the +3 SD threshold. IgA was correlated with IgG (Spearman's ρ = 0.74). The L1‐assay differentiated high, intermediate, low, and negative response groups from the blinded samples for all HPV genotypes ( p < 0.0001). Conclusion: The L1‐binding assay has the potential to be a scalable option for high‐throughput detection of broad‐spectrum HPV immunoglobulins, but further standardization and validation are needed.
- 1 September 2026
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 40 (19) , e70343
Open AccessPreliminary Development and Assessment of a Multiplex Assay for Human Papillomavirus Antibody Detection Using Commercial L1 Proteins
Background: Human papillomavirus (HPV)‐associated cancers are preventable with vaccination. Serologic assays monitor antibody responses, but their complexity and cost pose limitations when evaluating population level immunity. We developed an L1‐based assay for the detection of multiple type‐specific HPV antibodies. Methods: The Luminex‐based assay used recombinant L1 proteins from seven HPVs (HPV‐6/11/16/18/35/45/58) for the detection of type‐specific immunoglobulin (Ig)G and IgA. Cutoffs were established using plasma from infants and children. The assay was optimized and qualified using a sample set from a blinded proficiency panel developed at the Frederick National Laboratory for Cancer Research. Results: Sensitivity and specificity for anti‐HPV‐6/11/16/18/58 IgG were 100% at the Mean + 3 standard deviation [SD] and Mean + 5 SD thresholds. Sensitivity for HPV‐45 was 100% and 92.9% at the +3 SD and +5 SD thresholds, respectively. IgA detection showed moderate positivity among vaccinated individuals, with peak estimates of 96.4% (HPV‐11) and 85.7% (HPV‐58) at the +3 SD threshold. IgA was correlated with IgG (Spearman's ρ = 0.74). The L1‐assay differentiated high, intermediate, low, and negative response groups from the blinded samples for all HPV genotypes ( p < 0.0001). Conclusion: The L1‐binding assay has the potential to be a scalable option for high‐throughput detection of broad‐spectrum HPV immunoglobulins, but further standardization and validation are needed.
- Open Access
- 16 February 2025
- Published by Elsevier in Acta Biomaterialia
- Vol. 195, 522-535
Subcutaneous liposomal delivery improves monoclonal antibody pharmacokinetics in vivo
- 16 February 2025
- Published by Elsevier in Acta Biomaterialia
- Vol. 195, 522-535
Open AccessSubcutaneous liposomal delivery improves monoclonal antibody pharmacokinetics in vivo
- Open Access
A comprehensive engineering strategy improves potency and manufacturability of a near pan-neutralizing antibody against HIV
Anti-HIV envelope broadly neutralizing antibodies (bnAbs) are alternatives to conventional antiretrovirals with the potential to prevent and treat infection, reduce latent reservoirs, and/or mediate a functional cure. Clinical trials with “first generation” bnAbs used alone or in combination show promising antiviral effects but also highlight that additional engineering of “enhanced” antibodies will be required for optimal clinical utility, while preserving or enhancing cGMP manufacturing capability. Here we report the engineering of an anti-CD4 binding-site (CD4bs) bnAb, N49P9.3, purified from the plasma of an HIV elite-neutralizer. Through a series of rational modifications we produced a variant that demonstrates: enhanced potency; superior antiviral activity in combination with other bnAbs; low polyreactivity; and longer circulating half-life. Additional engineering for manufacturing produced a final variant, eN49P9, with properties conducive to cGMP production. Overall, these efforts demonstrate the feasibility of developing enhanced anti-CD4bs bnAbs with greatly improved antiviral properties as well as potential translational value.
Open AccessA comprehensive engineering strategy improves potency and manufacturability of a near pan-neutralizing antibody against HIV
Anti-HIV envelope broadly neutralizing antibodies (bnAbs) are alternatives to conventional antiretrovirals with the potential to prevent and treat infection, reduce latent reservoirs, and/or mediate a functional cure. Clinical trials with “first generation” bnAbs used alone or in combination show promising antiviral effects but also highlight that additional engineering of “enhanced” antibodies will be required for optimal clinical utility, while preserving or enhancing cGMP manufacturing capability. Here we report the engineering of an anti-CD4 binding-site (CD4bs) bnAb, N49P9.3, purified from the plasma of an HIV elite-neutralizer. Through a series of rational modifications we produced a variant that demonstrates: enhanced potency; superior antiviral activity in combination with other bnAbs; low polyreactivity; and longer circulating half-life. Additional engineering for manufacturing produced a final variant, eN49P9, with properties conducive to cGMP production. Overall, these efforts demonstrate the feasibility of developing enhanced anti-CD4bs bnAbs with greatly improved antiviral properties as well as potential translational value.
- 4 August 2022
- Published by Wolters Kluwer Health in Journal of Bone and Joint Surgery
- Vol. 105 (1) , e1
The First Description of Acute Compartment Syndrome, by Al-Zahrawi
Acute compartment syndrome (ACS) is defined as increased pressure within a confined compartmental space, leading to a decline in the perfusion pressure of the tissue within that compartment. To date, the commonly held belief has been that ACS was first described by Richard von Volkmann in 1881. However, we propose that ACS was originally described by Abul Qasim Al-Zahrawi approximately 900 years earlier.
- 4 August 2022
- Published by Wolters Kluwer Health in Journal of Bone and Joint Surgery
- Vol. 105 (1) , e1
The First Description of Acute Compartment Syndrome, by Al-Zahrawi
Acute compartment syndrome (ACS) is defined as increased pressure within a confined compartmental space, leading to a decline in the perfusion pressure of the tissue within that compartment. To date, the commonly held belief has been that ACS was first described by Richard von Volkmann in 1881. However, we propose that ACS was originally described by Abul Qasim Al-Zahrawi approximately 900 years earlier.